{
    "clinical_study": {
        "@rank": "65501", 
        "acronym": "Blossom", 
        "arm_group": [
            {
                "arm_group_label": "Ranibizumab 0.5 mg", 
                "arm_group_type": "Experimental", 
                "description": "Intravitreal injection of 0.05 ml of 10 mg/ml ranibizumab"
            }, 
            {
                "arm_group_label": "Sham injection", 
                "arm_group_type": "Sham Comparator", 
                "description": "Sham intravitreal injection"
            }
        ], 
        "brief_summary": {
            "textblock": "To provide efficacy and safety data on intravitreal injections of ranibizumab 0.5 mg in\n      patients with visual impairment due to macular edema secondary to BRVO"
        }, 
        "brief_title": "Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Branch Retinal Vein Occlusion (BRVO)", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Branch Retinal Vein Occlusion", 
        "condition_browse": {
            "mesh_term": [
                "Macular Edema", 
                "Retinal Vein Occlusion"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        \u2022 Patients with visual impairment secondary to branch retinal vein occlusion (BRVO) with a\n        BCVA between 19 and 73 letters in one eye and at least 35 letters in the other eye.\n\n        Exclusion Criteria:\n\n          -  Pregnant or nursing women or women of child bearing potential without using an\n             effective contraception\n\n          -  Stroke or myocard infarction within 3 months prior to study\n\n          -  History of malignancy within the past 5 years\n\n          -  Uncontrolled hypertension\n\n          -  Active infection or inflammation in any eye\n\n          -  monocular patients\n\n          -  use of corticosteroids for at least 30 days in the last 6 months\n\n          -  treatment with anti-angiogenic drugs in any eye within last 3 months\n\n          -  laser photocoagulation within the last few months\n\n          -  Other protocol defined inclusion/exclusion criteria may apply"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "282", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01976338", 
            "org_study_id": "CRFB002E2303"
        }, 
        "intervention": [
            {
                "arm_group_label": "Ranibizumab 0.5 mg", 
                "description": "intravitreal injection of 0.05 ml", 
                "intervention_name": "Ranibizumab 0.5 mg", 
                "intervention_type": "Drug", 
                "other_name": "Lucentis"
            }, 
            {
                "arm_group_label": "Sham injection", 
                "description": "Sham intravitreal injection", 
                "intervention_name": "Sham injection", 
                "intervention_type": "Other", 
                "other_name": "Sham"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": "BRVO, macular edema, vision impairment, retinal vein occlusion, ranibizumab", 
        "lastchanged_date": "February 18, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing", 
                        "zip": "100083"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing", 
                        "zip": "100730"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chongqing", 
                        "country": "China", 
                        "state": "Chongqing", 
                        "zip": "400042"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Harbin", 
                        "country": "China", 
                        "state": "Heilongjiang", 
                        "zip": "150086"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wuhan", 
                        "country": "China", 
                        "state": "Hubei", 
                        "zip": "430060"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wuhan", 
                        "country": "China", 
                        "state": "Hubei", 
                        "zip": "430070"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Changsha", 
                        "country": "China", 
                        "state": "Hunan", 
                        "zip": "410011"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nanjing", 
                        "country": "China", 
                        "state": "Jiangsu", 
                        "zip": "210029"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nanjing", 
                        "country": "China", 
                        "state": "Jiangsu", 
                        "zip": "210006"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nantong", 
                        "country": "China", 
                        "state": "Jiangsu", 
                        "zip": "226000"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nanchang", 
                        "country": "China", 
                        "state": "Jiangxi", 
                        "zip": "330006"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Qingdao", 
                        "country": "China", 
                        "state": "Shandong", 
                        "zip": "266011"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chengdu", 
                        "country": "China", 
                        "state": "Sichuan", 
                        "zip": "610041"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tianjin", 
                        "country": "China", 
                        "state": "Tianjin", 
                        "zip": "300070"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tianjin", 
                        "country": "China", 
                        "state": "Tianjin", 
                        "zip": "300020"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wenzhou", 
                        "country": "China", 
                        "state": "Zhejiang", 
                        "zip": "325027"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "zip": "100034"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "zip": "100176"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chongqing", 
                        "country": "China", 
                        "zip": "400038"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China", 
                        "zip": "200080"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China", 
                        "zip": "200092"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hongkong", 
                        "country": "Hong Kong"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bandung", 
                        "country": "Indonesia", 
                        "state": "Jawa Barat", 
                        "zip": "40117"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jakarta", 
                        "country": "Indonesia", 
                        "zip": "10430"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Manila", 
                        "country": "Philippines", 
                        "state": "Metro Manila", 
                        "zip": "1008"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Manila", 
                        "country": "Philippines", 
                        "zip": "1000"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Juan City", 
                        "country": "Philippines", 
                        "zip": "1500"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hanoi", 
                        "country": "Vietnam"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ho Chi Minh City", 
                        "country": "Vietnam"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "China", 
                "Hong Kong", 
                "Indonesia", 
                "Philippines", 
                "Vietnam"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized Double-masked, Phase III Study Assessing Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Visual Impairment Due to Macular Edema (ME) Secondary to Branch Retinal Vein Occlusion (BRVO) [Blossom]", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "+41613241111"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Assessment of efficacy of treatment with 0.5 mg ranibizumab prn compared to treatment with sham injection over 6 months. The change of BCVA will be assessed by the change from baseline BCVA to the average level of BCVA over all monthly assessments from month 1 to month 6", 
            "measure": "Change of Best Corrected Visual Acuity  (BCVA) in patients treated with ranibizumab 0.5 mg prn or sham injection", 
            "safety_issue": "No", 
            "time_frame": "Baseline, 6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01976338"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The Best Corrected Visual Acuity (BCVA) was tested using the Early Treatment Diabetic Retinopathy Study (ETDRS) Visual Acuity (VA) testing protocol. VA measurements were taken in a sitting position at an initial test distance of 4 meters using ETDRS charts. The overall BCVA score was calculated using the BCVA worksheet.", 
                "measure": "Average change of Best Corrected Visual Acuity (BCVA) in patients treated with ranibizumab 0.5 mg prn", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 12 months"
            }, 
            {
                "description": "The Best Corrected Visual Acuity (BCVA) was tested using the Early Treatment Diabetic Retinopathy Study (ETDRS) Visual Acuity (VA) testing protocol. VA measurements were taken in a sitting position at an initial test distance of 4 meters using ETDRS charts. The overall BCVA score was calculated using the BCVA worksheet.", 
                "measure": "Best Corrected Visual Acuity (BCVA) change over time", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Retinal thickness was assessed by Optical Coherence Tomography (OCT) and was analyzed by the central reading center.", 
                "measure": "Change in Central-Sub-Field- Thickness (CSFT)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 12 months"
            }, 
            {
                "description": "BCVA improvement of >= 5, >= 10, >=15 and >= 30 letters from baseline over time (month 1 through month 12)", 
                "measure": "Categorical BCVA improvement over time", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "BCVA loss < 15 letters from baseline over time (month 1 through month 12)", 
                "measure": "Percentage of patients with Best Corrected Visual Acuity (BCVA) loss < 15 letter", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Area of leakage was assessed by fluorescein angiography in conjunction with color fundus photography. Analysis was performed by the central reading center.", 
                "measure": "Number of patients with active leakage", 
                "safety_issue": "No", 
                "time_frame": "month 3, 6 and 12"
            }, 
            {
                "description": "Effect of treatment on absolute composite- and subscale scores and changes from baseline over time of vision related  quality of life assessed by the patient on the Vision Functioning Questionaire (VFQ-25)", 
                "measure": "The change in patient reported outcomes in NEI-VFQ-25 score (composite score and subscales) at month 3, 6 and 12 compared to baseline", 
                "safety_issue": "No", 
                "time_frame": "Baseline, months 3, 6 and 12"
            }, 
            {
                "measure": "Number of participants with Adverse events as a measure of Safety and Tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Number of re-treatments and re-treatment patterns (eg: duration of treatment-free intervals; duration of active treatment phase)", 
                "measure": "Number of re-treatments and re-treatment patterns", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}